Pyxis Oncology, Inc. SEC filings PYXS
Pyxis Oncology, Inc. has 356 filings in SEC EDGAR's recent list, going back to Jul 12, 2019. Its latest annual report, Form ARS, was filed on Apr 30, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 5, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 5, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations
|
Nov 5, 2026 | Nov 5, 2026 |
| 8-K |
Current report
Material agreement, Other events
|
Oct 1, 2026 | Sep 29, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 9, 2026 | Sep 9, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Sep 8, 2026 | Sep 3, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 13, 2026 | Aug 13, 2026 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 15, 2026 | Jun 15, 2026 |
| 8-K |
Current report
Results of operations
|
May 14, 2026 | May 14, 2026 |
| 8-K/A |
Amended current report
Officer or director change
|
Apr 30, 2026 | Feb 6, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 23, 2026 | Mar 23, 2026 |
| 8-K | Current report | Feb 6, 2026 | Feb 6, 2026 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Dec 18, 2025 | Dec 18, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 3, 2025 | Nov 3, 2025 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2025 | Aug 14, 2025 |
| 8-K |
Current report
Other events
|
Aug 4, 2025 | Aug 4, 2025 |
| 8-K |
Current report
Officer or director change
|
Jul 3, 2025 | Jul 1, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 18, 2025 | Jun 18, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
May 15, 2025 | May 15, 2025 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 24, 2025 | Mar 24, 2025 |
| 8-K |
Current report
Results of operations, Officer or director change, Regulation FD disclosure
|
Mar 18, 2025 | Mar 18, 2025 |
| 8-K |
Current report
Other events
|
Feb 26, 2025 | Feb 26, 2025 |
| 8-K |
Current report
Other events
|
Feb 4, 2025 | Feb 4, 2025 |
| 8-K |
Current report
Other events
|
Dec 19, 2024 | Dec 19, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Nov 20, 2024 | Nov 20, 2024 |
| 8-K |
Current report
Results of operations
|
Nov 12, 2024 | Nov 12, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Oct 23, 2024 | Oct 23, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2024 | Aug 14, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2024 | Jun 11, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 10, 2024 | Jun 10, 2024 |
| 8-K |
Current report
Results of operations
|
May 14, 2024 | May 14, 2024 |
| 8-K |
Current report
Other events
|
Mar 27, 2024 | Mar 27, 2024 |
| 8-K |
Current report
Other events
|
Mar 27, 2024 | Mar 27, 2024 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Mar 21, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Mar 13, 2024 | Mar 12, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Feb 28, 2024 | Feb 26, 2024 |
| 8-K |
Current report
Officer or director change
|
Nov 28, 2023 | Nov 27, 2023 |
| 8-K |
Current report
Results of operations
|
Nov 7, 2023 | Nov 7, 2023 |
| 8-K/A | Amended current report | Oct 27, 2023 | Aug 23, 2023 |
| 8-K |
Current report
Acquisition or sale of assets, Officer or director change, Regulation FD disclosure
|
Aug 23, 2023 | Aug 23, 2023 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2023 | Aug 11, 2023 |
| 8-K |
Current report
Other events
|
Aug 11, 2023 | Aug 11, 2023 |
| 8-K |
Current report
Officer or director change
|
Jun 30, 2023 | Jun 28, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jun 13, 2023 | Jun 13, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
May 24, 2023 | May 24, 2023 |
| 8-K |
Current report
Material agreement, Officer or director change, Regulation FD disclosure, Other events
|
May 24, 2023 | May 23, 2023 |
| 8-K |
Current report
Results of operations
|
May 11, 2023 | May 11, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 28, 2023 | Mar 28, 2023 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Mar 22, 2023 | Mar 22, 2023 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 16, 2023 | Mar 16, 2023 |
| 8-K |
Current report
Other events
|
Dec 1, 2022 | Dec 1, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 1, 2022 | Nov 1, 2022 |
| 8-K |
Current report
Material agreement, Unregistered share sale
|
Oct 7, 2022 | Oct 6, 2022 |
| 8-K |
Current report
Results of operations, Officer or director change
|
Aug 15, 2022 | Aug 15, 2022 |
| 8-K |
Current report
Officer or director change
|
Aug 9, 2022 | Aug 3, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 14, 2022 | Jun 13, 2022 |
| 8-K |
Current report
Results of operations
|
May 13, 2022 | May 13, 2022 |
| 8-K |
Current report
Officer or director change, Other events
|
Apr 14, 2022 | Apr 8, 2022 |
| 8-K |
Current report
Results of operations, Other events
|
Mar 29, 2022 | Mar 29, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 15, 2021 | Nov 15, 2021 |
Showing 59 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PYXS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1782223
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.